Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2012-05-10 AGM Information
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Resolutions at the annual general meetings in Medivir on 10 May 2012
AGM Information Classification · 99% confidence The document is explicitly titled 'Resolutions at the annual general meetings in Medivir on 10 May 2012' and details decisions made regarding the election of the board, remuneration, authorization to issue new shares, and approval of financial statements. These are the core components of an Annual General Meeting (AGM) outcome announcement. Therefore, the appropriate classification is AGM-R (AGM Information).
2012-05-10 English
Beslut vid årsstämma i Medivir den 10 maj 2012
AGM Information Classification · 99% confidence The document is explicitly titled "Beslut vid årsstämma i Medivir den 10 maj 2012" (Decisions at the Annual General Meeting in Medivir on May 10, 2012). It details the outcomes of the meeting, including the election of the board of directors, approval of remuneration, guidelines for executive compensation, authorization for share issuance, and the confirmation of the 2011 financial statements. These contents are characteristic of the formal documentation released following an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2012-05-10 Swedish
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period 1 January – 31 March 2012. It contains comprehensive financial statements, including income statements, balance sheet summaries, and detailed management commentary on business performance, R&D, and clinical trials. It is not a mere announcement (RPA) as it provides substantive financial data and analysis for the quarter. Therefore, it is classified as an Interim/Quarterly Report. Q1 2012
2012-05-10 Swedish
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report, 1 January – 31 March 2012' and contains comprehensive financial statements, including a consolidated profit performance table, balance sheet data, and detailed management analysis of business operations and R&D. It is a full quarterly report, not an announcement or a summary, and provides substantive financial data for the specified period. Q1 2012
2012-05-10 English
Medivir announces TMC435 in an expanded clinical collaboration
Regulatory Filings Classification · 95% confidence The document is a press release dated April 18, 2012, announcing an expansion of a clinical collaboration between Medivir and Bristol-Myers Squibb regarding the drug TMC435. It details ongoing and planned clinical studies (Phase II and Phase III) and provides background information on the drug and the disease (Hepatitis C). This content is characteristic of an announcement updating investors and the public on research and development progress, which aligns best with a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but given the format and content focus on operational/development news, RNS is the most appropriate general category for non-standard, non-financial core reports. It is not a 10-K (Annual Report), ER (Earnings Release), or IR (Interim Report) as it focuses on clinical trial updates rather than comprehensive financial performance for a period. It is not a DEF 14A (Remuneration) or DVA (Voting Results). Since it is a specific operational announcement that doesn't fit the highly specific categories like M&A (TAR) or Capital Change (CAP), the fallback category 'RNS' (Regulatory Filings/General Announcement) is selected.
2012-04-18 English
Medivir offentliggör utvidgat kliniskt samarbete för TMC435
Investor Presentation Classification · 92% confidence The document is a press release dated April 18, 2012, announcing an expanded clinical collaboration for the drug TMC435 involving Medivir and its partners (Janssen/Bristol-Myers Squibb). It details ongoing and planned clinical trials (Phase II and Phase III) for HCV treatment combinations. This type of announcement, focusing on R&D progress, clinical trial updates, and strategic partnerships, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a formal press release detailing strategic R&D progress and clinical pipeline status rather than just a brief announcement of a report (RPA) or a general regulatory filing (RNS), and given the detailed nature of the clinical program summary, 'Investor Presentation' (IP) is the most fitting category, as these press releases often serve the same function as a presentation slide deck in conveying strategic updates to investors. It is not a formal regulatory report like 10-K or IR.
2012-04-18 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.